Skip to main content

Table 2 Known-groups construct validity: mean index-based scores of EQ-5D-5L, EQ-5D-5Lcrosswalk, EQ-5D-3L, SF-6D and EQ VAS (and 95% confidence intervals) by patient characteristics

From: Validity of EQ-5D-5L health-related quality of life questionnaire in self-reported diabetes: evidence from a general population survey

 

N (%)

Mean (95%CI)

 

EQ-5D-5L

EQ-5D-5Lcrosswalk

EQ-5D-3L

SF-6D

EQ VAS

All

247 (100.0)

0.798 (0.766, 0.829)

0.754 (0.725, 0.783)

0.751 (0.717, 0.785)

0.633 (0.616, 0.649)

0.567 (0.541, 0.594)

Age (years)

      

 18–50

26 (10.5)

0.883 (0.807, 0.958)

0.846 (0.774, 0.917)

0.836 (0.732, 0.940)

0.728 (0.667, 0.789)

0.675 (0.572, 0.778)

 51–60

44 (17.8)

0.862 (0.804, 0.920)

0.815 (0.764, 0.867)

0.836 (0.782, 0.891)

0.643 (0.608, 0.679)

0.613 (0.548, 0.679)

 61–70

103 (41.7)

0.825 (0.777, 0.872)

0.771 (0.727, 0.816)

0.744 (0.690, 0.798)

0.637 (0.612, 0.662)

0.572 (0.533, 0.611)

  > 70

74 (30.0)

0.693 (0.627, 0.758)

0.662 (0.604, 0.720)

0.680 (0.610, 0.751)

0.586 (0.558, 0.614)

0.495 (0.452, 0.538)

Sex

      

 Female

132 (53.4)

0.772 (0.722, 0.822)

0.730 (0.685, 0.776)

0.729 (0.677, 0.781)

0.618 (0.595, 0.640)

0.546 (0.509, 0.583)

 Male

115 (46.6)

0.828 (0.792, 0.864)

0.782 (0.749, 0.815)

0.777 (0.733, 0.820)

0.650 (0.625, 0.674)

0.591 (0.553, 0.630)

Diabetes treatment

      

 No medication

59 (23.9)

0.873 (0.818, 0.929)

0.827 (0.774, 0.881)

0.813 (0.749, 0.878)

0.669 (0.634, 0.704)

0.631 (0.577, 0.686)

 OAD

120 (48.6)

0.795 (0.749, 0.842)

0.749 (0.707, 0.792)

0.756 (0.707, 0.804)

0.634 (0.609, 0.658)

0.575 (0.537, 0.613)

 Insulin

55 (22.3)

0.727 (0.655, 0.799)

0.690 (0.627, 0.754)

0.672 (0.590, 0.754)

0.601 (0.567, 0.635)

0.493 (0.438, 0.548)

 Combined treatment

13 (5.3)

0.781 (0.652, 0.910)

0.738 (0.630, 0.845)

0.760 (0.615, 0.905)

0.590 (0.531, 0.649)

0.519 (0.418, 0.621)

Education level

      

 Primary

58 (23.5)

0.696 (0.622, 0.771)

0.658 (0.592, 0.724)

0.643 (0.552, 0.735)

0.575 (0.543, 0.607)

0.499 (0.445, 0.553)

 Secondary

146 (59.1)

0.817 (0.776, 0.858)

0.772 (0.734, 0.810)

0.774 (0.733, 0.815)

0.643 (0.621, 0.665)

0.584 (0.549, 0.619)

 High

43 (17.4)

0.871 (0.823, 0.918)

0.824 (0.782, 0.867)

0.818 (0.758, 0.877)

0.674 (0.636, 0.711)

0.603 (0.542, 0.663)

EQ VAS

      

 0–24

17 (6.9)

0.311 (0.091, 0.531)

0.310 (0.111, 0.510)

0.195 (− 0.049, 0.438)

0.490 (0.447, 0.534)

0.124 (0.084, 0.163)

 25–49

39 (15.8)

0.665 (0.595, 0.734)

0.635 (0.578, 0.692)

0.648 (0.563, 0.733)

0.516 (0.486, 0.546)

0.350 (0.333, 0.367)

 50–74

136 (55.1)

0.847 (0.819, 0.875)

0.795 (0.770, 0.820)

0.791 (0.761, 0.822)

0.642 (0.624, 0.659)

0.572 (0.557, 0.586)

 75–100

55 (22.3)

0.922 (0.880, 0.964)

0.876 (0.831, 0.920)

0.896 (0.863, 0.930)

0.736 (0.701, 0.772)

0.848 (0.827, 0.869)

  1. OAD oral antidiabetic drugs